
<!doctype html>
<html>
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0">
    <title>Dengue Vaccine</title>
    <link rel="stylesheet" type="text/css" href="../css/style.css">
    <link rel="stylesheet" href="../css/ir_black.css">
    <script type="text/javascript" src="../js/slideshow.js"></script>
    <script src="../js/highlight.pack.js"></script>
    <script src="../js/d3.v3.min.js"></script>
    <script>hljs.initHighlightingOnLoad();</script>
  </head>
  <body>
    <div class="progress">
      <div class="progress-bar"></div>
    </div>

    <div class="slide">
      <section>
        <h1>Dengue Vaccine: Problems and Prospects</h1>
        <h2>&nbsp;</h2>
        <h2>Christopher Wetherill</h2>
        <h2>TBMH 5054</h2>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Some background</h3>
        <ul>
          <li>Eleven kb ssRNA virus with four antigenically distinct serotypes</li>
          <li>Circulates throughout Southeast Asia, Africa, and the Americas</li>
          <li>Genome encodes 3 structural (capsid, C, membrane, M, and envelope, E) and 7 non-structural proteins</li>
          <li>E protein is a major target of many dengue vaccine candidates (contains a domain on virion surface with multiple type-specific neutralizing epitopes)</li>
        </ul>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>The Dengue Genome</h3>
        <br />
        <img src="./assets/genome.png" />
        <br />
        <span class="cite">doi: 10.1586/14760584.2013.815412</span>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Impediments to Vaccine Development</h3>

        <p>Numerous difficulties in developing an effective DENV vaccine have been identified, including:</p>
        <ul>
          <li>The epidemiology of the 4 DENV serotypes;
            <ul>
              <li>Following WWII, DENV has spread rapidly and DENV 1&ndash;4 serotypes now co-circulate in several regions</li>
              <li>Many regions lack adequate dengue surveillance</li>
            </ul>
          </li>
          <li>The complex, poorly understood immunopathogenic responses infection elicits (e.g., cytokine storm); and</li>
          <li>The lack of validated animal models of dengue</li>
        </ul>
        
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Current Limits to Animal Models</h3>
        <ul>
          <li>Immunocompetent mice fail to develop clinical symptoms (analogous to human) following DENV infection</li>
          <li>Severe combined immunodeficiency mice have been shown to support DENV replication</li>
          <li>&Delta;IFN receptor mice support viral replication; however, lack of IFN receptors limits possible immune responses</li>
          <li>Non-human primates can be naturally infected, but are asymptomatic</li>
          <li>Other animal models including rabbits and miniature swine are being investigated</li>
        </ul>        
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Vaccine Candidates: (Pre-)Clinical Development</h3>
        <ul>
          <li>Live attenuated vaccines
            <ul>
              <li>Several phase 1 and 2 trials of mono- and tetravalent formulations ongoing</li>
              <li>Current LAVs for other flaviviruses (yellow valley fever virus and Japanese encephalitis virus) have proven safe and effective</li>
            </ul>
          </li>
          <li>Purified inactivated vaccines
            <ul>
              <li>Shown to induce neutralizing antibodies</li>
              <li>Typically more expensive to manufacture, but safe in immunosuppressed individuals</li>
            </ul>
          </li>
        </ul>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Vaccine Candidates: (Pre-)Clinical Development</h3>
        <ul>
          <li>Recombinant subunit vaccines
            <ul>
              <li>Similar benefits to purified inactivated vaccines</li>
              <li>Primarily based on E protein of DENV</li>
            </ul>
          </li>
          <li>Virus vectored and VLP-based vaccines
            <ul>
              <li>More closely approximates natural presentation of DENV surface antigens</li>
              <li>Shows significant boosts in neutralizing antibody responses following challenge</li>
              <li>May be useful in a prime-boost strategy with LAV as the booster</li>
            </ul>
          </li>
        </ul>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Vaccine Candidates: (Pre-)Clinical Development</h3>
        <ul>
          <li>DNA vaccines
            <ul>
              <li>Consist of gene sequence cloned into plasmid backbone</li>
              <li>Plasmid taken up by APCs which then express plasmid-encoded genes to generate target antigens</li>
            </ul>
          </li>
          <li>Heterologous prime-boost strategies
            <ul>
              <li>Initial immunization with one type of vaccine is followed by boost with a second</li>
              <li>Strategy has shown improved immunogenicity for other pathogens</li>
              <li>Order of administration and specific antigens used may be critical in determing efficacy</li>
            </ul>
          </li>
        </ul>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Challenges to Vaccine Implementation</h3>
        <ul>
          <li>Cost always a major limiting factor
            <ul>
              <li>Some indication that governments would be willing to pay $0.50&mdash;$1.00 per dose</li>
              <li>Estimates suggest cost of production $0.20&mdash;$1.75 per dose</li>
              <li>Cost of refrigeration can hinder widespread adoption</li>
            </ul>
          </li>
          <li>May see drop-off if follow-up boosters are required</li>
          <li>Possibility of immune interference by DENV vaccine when given in combination with other flavivirus vaccines</li>
        </ul>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Reducing Barriers to Market</h3>
        <img src="./assets/his.png" />
        <br />
        <span class="cite">doi: 10.1016/j.vaccine.2013.12.061</span>
      </section>
    </div>


    <div class="slide hidden">
      <section>
        <h3>Perils of Imperfect Vaccines</h3>
        <br />
        <img src="./assets/superbug.png" />
        <br />
        <span class="cite">doi: :10.1016/j.vaccine.2013.11.020</span>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>References</h3>

        <span class="refs">Durham, D., Mbah, M., Medlock, J., Luz, P., Meyers, L., Paltiel, A., & Galvani, A. (2013). Dengue dynamics and vaccine cost-effectiveness in Brazil. <em>Vaccine, 31</em>, 3957 - 3961. doi: 10.1016/j.vaccine.2013.06.036</span>

        <span class="refs">Khalil, S., Tonkin, D., Mattocks, M., Snead, A., Johnston, R., & White, L. (2014). A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model. <em>Vaccine, 32</em>, 4068 - 4074. doi: 10.1016/j.vaccine.2014.05.053</span>

        <span class="refs">Mahoney, R. (2014). The introduction of new vaccines into developing countries. V: Will we lose a decade or more in the introduction of dengue vaccines to developing countries? <em>Vaccine, 34</em>, 904 - 908. doi: 10.1016/j.vaccine.2013.12.061</span>

        <span class="refs">McArthur, M., Sztein, M., & Edelman, R. (2013). Dengue vaccines: recent developments, ongoing challenges and current candidates <em>Expert Reviews in Vaccines, 12</em>, 933 - 953. doi: 10.1586/14760584.2013.815412</span>

        <span class="refs">Rodriguez-Barraquer, I., Mier-y-Teran-Romero, L., Schwartz, I., Burke, D., & Cummings, D. (2014). Potential opportunities and perils of imperfect dengue vaccines. <em>Vaccine, 32</em>, 514 - 520. doi: 10.1016/j.vaccine.2013.11.020</span>        
      </section>
    </div>

    <script>
      var data = [];
      var slideLen = document.getElementsByClassName('slide').length;
      for(i = 1; i <= slideLen; i++) {
      	data.push(i);
      }

      d3.selectAll("div.slide")
        .data(data)
        .attr("id", function(d) { return "slide-" + d; });

      d3.selectAll("section").attr("class", "slide-content");
    </script>

    <div class="controls">
      <div class="arrow prev"></div>
      <div class="arrow next"></div>
    </div>
  </body>
</html>